Payment overview · 2025
General Payments
$682.66
37 reported records · 14 companies
Healthcare provider profile · identity verified
Mason Tootell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WARREN, PA · NPI 1568675270
Verified facts
What the public records show
CMS Open Payments records show Mason Tootell, M.D. received $682.66 in general payments during 2025 across 37 reported records.
PFIZER INC. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $111.37 | 16.3% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.38 | 14.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.61 | 11.7% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.63 | 9.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.29 | 7.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.97 | 6.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $38.98 | 5.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.51 | 5.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.95 | 5.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $30.32 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.58 | 4.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.24 | 3.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.76 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.07 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $682.66 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $101.38 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $96.64 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.63 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $63.62 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.97 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $38.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.02 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $30.32 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.92 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 214 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 137 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 133 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
137 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
142 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
214 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 732 | 183 |
| Lisinopril | Lisinopril | 647 | 162 |
| Gabapentin | Gabapentin | 613 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 493 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 486 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 392 | 98 |
| Omeprazole | Omeprazole | 381 | 83 |
| Furosemide | Furosemide | 348 | 95 |
| Metformin Hcl | Metformin Hcl | 329 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 306 | 83 |
| Potassium Chloride | Potassium Chloride | 264 | 64 |
| Losartan Potassium | Losartan Potassium | 255 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 254 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 60 |
| Eliquis | Apixaban | 214 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 214 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 50 |
| Atenolol | Atenolol | 184 | 44 |
| Lorazepam | Lorazepam | 182 | 35 |
| Allopurinol | Allopurinol | 176 | 38 |
| Simvastatin | Simvastatin | 170 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 37 |
| Warfarin Sodium | Warfarin Sodium | 169 | 24 |
| Tramadol Hcl | Tramadol Hcl | 159 | 44 |
| Pregabalin | Pregabalin | 158 | 29 |
| Meloxicam | Meloxicam | 157 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 44 |
| Morphine Sulfate Er | Morphine Sulfate | 149 | 15 |
| Trazodone Hcl | Trazodone Hcl | 149 | 27 |
| Carvedilol | Carvedilol | 144 | 27 |
| Trulicity | Dulaglutide | 142 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 141 | 19 |
| Farxiga | Dapagliflozin Propanediol | 137 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 136 | 20 |
| Mounjaro | Tirzepatide | 133 | 28 |
| Alprazolam | Alprazolam | 121 | 23 |
| Sertraline Hcl | Sertraline Hcl | 117 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 23 |
| Montelukast Sodium | Montelukast Sodium | 112 | 35 |
| Famotidine | Famotidine | 110 | 28 |
| Ezetimibe | Ezetimibe | 108 | 20 |
| Topiramate | Topiramate | 107 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 26 |
| Spironolactone | Spironolactone | 99 | 22 |
| Sucralfate | Sucralfate | 96 | 23 |
| Chlorthalidone | Chlorthalidone | 90 | 17 |
| Baclofen | Baclofen | 81 | 16 |
| Alendronate Sodium | Alendronate Sodium | 78 | 16 |
| Ozempic | Semaglutide | 78 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 22 |
| Fentanyl | Fentanyl | 74 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 74 | 13 |
| Celecoxib | Celecoxib | 73 | 15 |
| Nystatin | Nystatin | 72 | 23 |
| Jardiance | Empagliflozin | 71 | suppressed |
| Xarelto | Rivaroxaban | 71 | 21 |
| Prednisone | Prednisone | 66 | 30 |
| Diazepam | Diazepam | 65 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 61 | 12 |
| Mirtazapine | Mirtazapine | 60 | 17 |
| Bumetanide | Bumetanide | 59 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 12 |
| Synthroid | Levothyroxine Sodium | 56 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 53 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 14 |
| Xtampza Er | Oxycodone Myristate | 52 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 17 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Methadone Hcl | Methadone Hcl | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Oxycontin | Oxycodone Hcl | 38 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Methocarbamol | Methocarbamol | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 35 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Lidocaine | Lidocaine | 32 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 21 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 11 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Roflumilast | Roflumilast | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Restasis | Cyclosporine | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 17 |
| Finasteride | Finasteride | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Vivitrol | Naltrexone Microspheres | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $682.66 · 37 records | PFIZER INC. | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ohtuvayre, PAXLOVID, PROLIA, QULIPTA, REPATHA, Tymlos, UBRELVY, VOQUEZNA, WATCHMAN FLX, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error